Logo image of BRCC

BRC INC-A (BRCC) Stock Fundamental Analysis

NYSE:BRCC - New York Stock Exchange, Inc. - US05601U1051 - Common Stock - Currency: USD

2.57  +0.04 (+1.58%)

After market: 2.61 +0.04 (+1.56%)

Fundamental Rating

2

Overall BRCC gets a fundamental rating of 2 out of 10. We evaluated BRCC against 90 industry peers in the Food Products industry. BRCC may be in some trouble as it scores bad on both profitability and health. BRCC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BRCC had negative earnings in the past year.
BRCC had a positive operating cash flow in the past year.
BRCC had negative earnings in 4 of the past 5 years.
In multiple years BRCC reported negative operating cash flow during the last 5 years.
BRCC Yearly Net Income VS EBIT VS OCF VS FCFBRCC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 -50M -100M

1.2 Ratios

The Return On Assets of BRCC (-2.12%) is worse than 70.24% of its industry peers.
BRCC's Return On Equity of -34.10% is on the low side compared to the rest of the industry. BRCC is outperformed by 78.57% of its industry peers.
Industry RankSector Rank
ROA -2.12%
ROE -34.1%
ROIC N/A
ROA(3y)-19.91%
ROA(5y)-11.62%
ROE(3y)-245%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BRCC Yearly ROA, ROE, ROICBRCC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -100 -200 -300

1.3 Margins

The Gross Margin of BRCC (37.62%) is better than 83.33% of its industry peers.
BRCC's Gross Margin has declined in the last couple of years.
BRCC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 37.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.19%
GM growth 5YN/A
BRCC Yearly Profit, Operating, Gross MarginsBRCC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 20 -20 40

More info and screens

2

2. Health

2.1 Basic Checks

BRCC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BRCC has been increased compared to 1 year ago.
The debt/assets ratio for BRCC is higher compared to a year ago.
BRCC Yearly Shares OutstandingBRCC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 50M 100M 150M 200M
BRCC Yearly Total Debt VS Total AssetsBRCC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

BRCC has an Altman-Z score of 2.53. This is not the best score and indicates that BRCC is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.53, BRCC perfoms like the industry average, outperforming 53.57% of the companies in the same industry.
The Debt to FCF ratio of BRCC is 7.06, which is on the high side as it means it would take BRCC, 7.06 years of fcf income to pay off all of its debts.
BRCC's Debt to FCF ratio of 7.06 is in line compared to the rest of the industry. BRCC outperforms 55.95% of its industry peers.
A Debt/Equity ratio of 3.38 is on the high side and indicates that BRCC has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 3.38, BRCC is doing worse than 94.05% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 3.38
Debt/FCF 7.06
Altman-Z 2.53
ROIC/WACCN/A
WACC8.55%
BRCC Yearly LT Debt VS Equity VS FCFBRCC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M -100M

2.3 Liquidity

BRCC has a Current Ratio of 1.14. This is a normal value and indicates that BRCC is financially healthy and should not expect problems in meeting its short term obligations.
BRCC has a worse Current ratio (1.14) than 69.05% of its industry peers.
BRCC has a Quick Ratio of 1.14. This is a bad value and indicates that BRCC is not financially healthy enough and could expect problems in meeting its short term obligations.
BRCC has a worse Quick ratio (0.58) than 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 0.58
BRCC Yearly Current Assets VS Current LiabilitesBRCC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 72.41% over the past year.
BRCC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.68%.
The Revenue has been growing by 34.14% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)72.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)9.68%
Revenue growth 3Y34.14%
Revenue growth 5YN/A
Sales Q2Q%-2.32%

3.2 Future

The Earnings Per Share is expected to grow by 20.75% on average over the next years. This is a very strong growth
BRCC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.06% yearly.
EPS Next Y95.28%
EPS Next 2Y38.04%
EPS Next 3Y28.58%
EPS Next 5Y20.75%
Revenue Next Year-1.97%
Revenue Next 2Y1.88%
Revenue Next 3Y5.42%
Revenue Next 5Y11.06%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BRCC Yearly Revenue VS EstimatesBRCC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M
BRCC Yearly EPS VS EstimatesBRCC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 1 -1 2 3 4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BRCC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BRCC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BRCC Price Earnings VS Forward Price EarningsBRCC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40 -60 -80 -100

4.2 Price Multiples

BRCC's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. BRCC is more expensive than 67.86% of the companies in the same industry.
BRCC's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 59.49
EV/EBITDA 96.85
BRCC Per share dataBRCC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as BRCC's earnings are expected to grow with 28.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.04%
EPS Next 3Y28.58%

More info and screens

0

5. Dividend

5.1 Amount

BRCC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRC INC-A

NYSE:BRCC (2/21/2025, 8:04:09 PM)

After market: 2.61 +0.04 (+1.56%)

2.57

+0.04 (+1.58%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)03-03 2025-03-03/amc
Inst Owners52.7%
Inst Owner Change-96.72%
Ins Owners21.35%
Ins Owner Change-0.66%
Market Cap546.74M
Analysts78.33
Price Target4.93 (91.83%)
Short Float %15.32%
Short Ratio12.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49.38%
Min EPS beat(2)42.33%
Max EPS beat(2)56.43%
EPS beat(4)3
Avg EPS beat(4)-48.1%
Min EPS beat(4)-414.83%
Max EPS beat(4)123.68%
EPS beat(8)4
Avg EPS beat(8)-44.67%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-6.24%
Min Revenue beat(2)-13.52%
Max Revenue beat(2)1.03%
Revenue beat(4)1
Avg Revenue beat(4)-4.6%
Min Revenue beat(4)-13.52%
Max Revenue beat(4)1.03%
Revenue beat(8)2
Avg Revenue beat(8)-3.5%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.5%
PT rev (3m)4.5%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-50%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.54%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.35
P/FCF 59.49
P/OCF 17.54
P/B 37.63
P/tB 38.63
EV/EBITDA 96.85
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)0.04
FCFY1.68%
OCF(TTM)0.15
OCFY5.7%
SpS1.9
BVpS0.07
TBVpS0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.12%
ROE -34.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 37.62%
FCFM 2.27%
ROA(3y)-19.91%
ROA(5y)-11.62%
ROE(3y)-245%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.19%
GM growth 5YN/A
F-Score6
Asset Turnover1.73
Health
Industry RankSector Rank
Debt/Equity 3.38
Debt/FCF 7.06
Debt/EBITDA 7.86
Cap/Depr 234.63%
Cap/Sales 5.43%
Interest Coverage N/A
Cash Conversion 499.65%
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 0.58
Altman-Z 2.53
F-Score6
WACC8.55%
ROIC/WACCN/A
Cap/Depr(3y)578%
Cap/Depr(5y)512.12%
Cap/Sales(3y)8.42%
Cap/Sales(5y)6.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y95.28%
EPS Next 2Y38.04%
EPS Next 3Y28.58%
EPS Next 5Y20.75%
Revenue 1Y (TTM)9.68%
Revenue growth 3Y34.14%
Revenue growth 5YN/A
Sales Q2Q%-2.32%
Revenue Next Year-1.97%
Revenue Next 2Y1.88%
Revenue Next 3Y5.42%
Revenue Next 5Y11.06%
EBIT growth 1Y94.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year198.02%
EBIT Next 3Y47.76%
EBIT Next 5Y32.42%
FCF growth 1Y108.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y141.02%
OCF growth 3YN/A
OCF growth 5YN/A